• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Science & Environment Medical Research

Phase 2 results suggest continued study of novel first-line combo for advanced kidney cancer

January 17, 2025
in Medical Research
Reading Time: 2 mins read
A A
0
Phase 2 results suggest continued study of novel first-line combo for advanced kidney cancer
3
SHARES
6
VIEWS
Share on FacebookShare on Twitter


Phase 2 results suggest continued study of novel first-line combo for advanced kidney cancer
Credit: The Lancet Oncology (2025). DOI: 10.1016/S1470-2045(24)00649-1

In the open-label phase 2 LITESPARK-003 study, led by Dana-Farber Cancer Institute’s Toni Choueiri, MD, researchers investigated for the first time the combination of cabozantinib, an anti-angiogenic agent, plus belzutifan, a first-in-class HIF-2α inhibitor. The findings are published in The Lancet Oncology journal.

The researchers previously reported results for cohort 2 of the trial, which includes patients previously treated with immunotherapy. This study reports results for cohort 1, which includes patients who have not yet received treatment for advanced kidney cancer.

After a median follow up of 24 months, 70% of patients had a confirmed objective response, with 4 of 50 patients experiencing a complete response and 31 of 50 experiencing a partial response. Seven of the 50 patients had serious treatment-related adverse events, though they were manageable.

Current first-line treatment for advanced clear-cell renal cell carcinoma includes anti-PD1 or anti-PD-L1 immunotherapy in combination with a CTLA-4 inhibitor or a VEGF tyrosine kinase inhibitor such as cabozantanib. These options have improved outcomes in patients; however, not all patients respond, and some responses do not last. This study’s results suggest that further investigation of this novel combination as first-line therapy option is warranted.

More information:
Toni K Choueiri et al, Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study, The Lancet Oncology (2025). DOI: 10.1016/S1470-2045(24)00649-1

Provided by
Dana-Farber Cancer Institute


Citation:
Phase 2 results suggest continued study of novel first-line combo for advanced kidney cancer (2025, January 17)
retrieved 17 January 2025
from https://medicalxpress.com/news/2025-01-phase-results-line-combo-advanced.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.




Phase 2 results suggest continued study of novel first-line combo for advanced kidney cancer
Credit: The Lancet Oncology (2025). DOI: 10.1016/S1470-2045(24)00649-1

In the open-label phase 2 LITESPARK-003 study, led by Dana-Farber Cancer Institute’s Toni Choueiri, MD, researchers investigated for the first time the combination of cabozantinib, an anti-angiogenic agent, plus belzutifan, a first-in-class HIF-2α inhibitor. The findings are published in The Lancet Oncology journal.

The researchers previously reported results for cohort 2 of the trial, which includes patients previously treated with immunotherapy. This study reports results for cohort 1, which includes patients who have not yet received treatment for advanced kidney cancer.

After a median follow up of 24 months, 70% of patients had a confirmed objective response, with 4 of 50 patients experiencing a complete response and 31 of 50 experiencing a partial response. Seven of the 50 patients had serious treatment-related adverse events, though they were manageable.

Current first-line treatment for advanced clear-cell renal cell carcinoma includes anti-PD1 or anti-PD-L1 immunotherapy in combination with a CTLA-4 inhibitor or a VEGF tyrosine kinase inhibitor such as cabozantanib. These options have improved outcomes in patients; however, not all patients respond, and some responses do not last. This study’s results suggest that further investigation of this novel combination as first-line therapy option is warranted.

More information:
Toni K Choueiri et al, Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study, The Lancet Oncology (2025). DOI: 10.1016/S1470-2045(24)00649-1

Provided by
Dana-Farber Cancer Institute


Citation:
Phase 2 results suggest continued study of novel first-line combo for advanced kidney cancer (2025, January 17)
retrieved 17 January 2025
from https://medicalxpress.com/news/2025-01-phase-results-line-combo-advanced.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



Tags: Health ResearchHealth Research NewsHealth ScienceMedicine ResearchMedicine Research NewsMedicine Science
Previous Post

Amid the firestorm, all around L.A., signs of gratitude, love appear

Next Post

Environment Oregon’s 2025 legislative agenda

Related Posts

doctor chat

Clinicians can ‘chat’ with medical records through new AI software, ChatEHR

June 6, 2025
5
FDA launches AI tool for its employees

FDA launches AI tool for its employees

June 6, 2025
2
Next Post
sea turtle chasing plastic bag

Environment Oregon’s 2025 legislative agenda

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024

Police ID man who died after Corso Italia fight

December 23, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0
FuelCell (FCEL) Q2 2025 Earnings Call Transcript

FuelCell (FCEL) Q2 2025 Earnings Call Transcript todayheadline

June 6, 2025

Arlo technologies CFO sells shares worth $1.18 million todayheadline

June 6, 2025
How Shoott Found a Customer Base It Wasn't Expecting

How Shoott Found a Customer Base It Wasn’t Expecting todayheadline

June 6, 2025
Karl Rove: Trump’s economic 'gyrations' pushing America to the 'stage of exhaustion'

Karl Rove: Trump’s economic ‘gyrations’ pushing America to the ‘stage of exhaustion’ todayheadline

June 6, 2025

Recent News

FuelCell (FCEL) Q2 2025 Earnings Call Transcript

FuelCell (FCEL) Q2 2025 Earnings Call Transcript todayheadline

June 6, 2025
3

Arlo technologies CFO sells shares worth $1.18 million todayheadline

June 6, 2025
6
How Shoott Found a Customer Base It Wasn't Expecting

How Shoott Found a Customer Base It Wasn’t Expecting todayheadline

June 6, 2025
5
Karl Rove: Trump’s economic 'gyrations' pushing America to the 'stage of exhaustion'

Karl Rove: Trump’s economic ‘gyrations’ pushing America to the ‘stage of exhaustion’ todayheadline

June 6, 2025
4

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Cybersecurity
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

FuelCell (FCEL) Q2 2025 Earnings Call Transcript

FuelCell (FCEL) Q2 2025 Earnings Call Transcript todayheadline

June 6, 2025

Arlo technologies CFO sells shares worth $1.18 million todayheadline

June 6, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co